

Events during the absorption phase of a neutralization assay are predictive of protection in the SHIV – rhesus macaque model.

David Davis, Wim Koornstra, Daniella Mortier, Zahra Fagrouch, Ernst Verschoor, Marjorie Robert-Guroff, Indresh Srivastava, Susan Barnett, Jonathan Heeney, Willy Bogers.


# Objective

*An assay correlating neutralizing antibodies with protection would facilitate the development of an HIV vaccine.*


# SHIV challenge studies

	Rhesus macaques	Challenge
Trial 1:	Protein prime, peptide boost Imported: 16 + 4 controls	Week 55 i. ven SHIVSF162P4
Trial 2:	Protein prime, mimotope boost Indian: 15 + 5 controls	Week 24 i. rect SHIV SF162P4
Trial 3:	Mimotope prime, protein boost Indian: 15 + 5 controls	Week 24 i. rect SHIV SF162P4
Trial 4:	Adeno/mucosal prime, protein boost Imported: 8 + 4 controls	Week 44 i. rect SHIV SF162P4
Trial 5:	Alpha virus prime, protein boost Mixture: 32 + 8 controls	Week 44 i. rect SHIV SF162P4

# Areas under curve




# Positive example





# Negative example



# Summary: Coefs. of Determination

Trial	Serum taken:		Day of challenge
	- 6 weeks	- 2 weeks	
1	0.3729	0.4221	Not available
2	Not available	0.01239	0.0001344
3	Not available	0.1362	0.1182
4	0.8602	Not available	0.6377
5	0.4947	0.5510	0.5438



# Potential explanations



Neutralizing antibodies are not protective;

Reduction in area under viral load curve does not quantify protection;

Protection not related to concentration of neutralizing antibody;

Qualitative differences between protective and other antibodies.

# Selection of sera




log<sub>10</sub> neutralizing antibody titre

# Neutralization reaction


Infectious virus + antibody  $\rightleftharpoons$  Non-infectious virus

Mixture exposed to cells to quantify proportion of virus retaining infectivity.


# Extrapolation back to zero absorption.




# Kinetics with serum from protected macaque.



# Kinetics with serum from infected macaque.



# Ratios (so far)



Expected ratios = 2.5

■ Protected    Infected    △

# Conclusions

*Antibodies which conform to the traditional definition of neutralization are more likely to be associated with protection.*



# Consortium

Biomedical Primate Research Centre,  
Rijswijk, The Netherlands.

Novartis Vaccines & Diagnostics, Inc.  
Cambridge, MA.

Jon Heeney,  
Wim Koornstra,  
Willy Bogers,  
Daniella Mortier,  
Zahra Fagrouch,  
Ernst Verschoor.

Susan Barnett,  
Indresh Srivastava.

NIH, National Cancer Institute, Bethesda, MD.

Marjorie Robert-Guroff

Funded by:

National Institutes of Health, Washington; European Commission.

The way to get something done is not to mind who gets the credit for doing it.

Benjamin Jowett, Master of Balliol College, Oxford